Bodycote (LSE:BOY) is in the spotlight because it has become the subject of a contested private Capital takeover. On 1 September 2026 the heat treatment specialist's board unanimously backed a cash offer worth 940p per share from Veritas Capital, valuing the company's shares at about £1.65 billion. The board's decision followed a month in which Veritas and CVC Capital Partners had both tabled rival proposals.

The contest is not necessarily over. After the Veritas deal was announced, CVC said it was "evaluating its options" and advised Bodycote shareholders to "take no action for the time being". The shares rose 4.4 per cent on the news and traded above the Veritas price, a sign that some investors were positioning for a higher bid.

Behind the bidding sits a Business that has been reshaping itself, with interim results in July showing stronger margins and double-digit growth in aerospace and defence.

What Bodycote Does and Why Buyers Want It

Bodycote describes itself as the world's largest provider of heat treatment and specialist thermal processing services. It runs about 130 facilities in 22 countries, employs about 4,000 people, and treats metal components for customers in aerospace, defence, industrial gas turbines, medical devices, energy and automotive. The work hardens and protects parts so that they meet demanding specifications.

In the 2025 financial year Bodycote reported Revenue of £727.1 million and adjusted EBITDA of £184.7 million, according to the Veritas offer announcement. Those cash flows, combined with a network that would be expensive to replicate, help explain why two large private capital houses were prepared to compete.

How the Bidding Unfolded

Bodycote confirmed on 5 August 2026 that it had received two possible cash offers. CVC had proposed 915p per share (907.8p in cash plus the 7.2p interim dividend) and Veritas 914p (906.8p plus the dividend). The board said it would be minded to back either proposal if a firm offer were made, and both parties were given access to due diligence. The shares jumped 23 per cent to close at 923p that day. Under the Takeover Code, both suitors faced a deadline of 5pm on 2 September 2026 to announce a firm offer or walk away.

Veritas moved first. Its firm offer, made through Vulcan Alpha Bidco, comprises 932.8p in cash plus the 7.2p interim dividend, for a total of 940p. The company said this represented a 45.1 per cent premium to the 647.8p closing price on 7 July 2026, a 37.5 per cent premium to the three-month volume-weighted average price to 21 May 2026, and a 25.3 per cent premium to the 750.2p close on 4 August 2026, the day before the approaches were confirmed. The Enterprise value is about £1.85 billion. According to the announcement, CVC had improved its proposal to 915p before Veritas raised its own terms and became the sole board-backed bidder.

Trading Momentum Behind the Offer

The takeover interest arrived as Bodycote's operations were improving. In its interim results for the six months to 30 June 2026, published on 27 July, the company reported revenue of £381.2 million, up 3.3 per cent on a reported basis and 6.5 per cent organically. Core organic growth was 9.6 per cent. Adjusted operating profit rose 10.7 per cent to £61.0 million, lifting the adjusted operating Margin by 110 basis points to 16.0 per cent. Adjusted Earnings Per Share climbed 18.3 per cent to 25.2p, and the Interim Dividend rose 4.3 per cent to 7.2p.

The growth came mainly from the Specialist Technologies division, where revenue grew 16.7 per cent organically to £121.2 million at a 26.1 per cent operating margin. Aerospace and defence revenue grew by 25 per cent organically and industrial gas turbines by 11 per cent. Chief executive Jim Fairbairn pointed to strong Demand across target markets, partly offset by what he called "ongoing structural weakness in Western European Automotive", where revenue fell 4 per cent.

Self-help is also contributing. Under its Optimise programme, Bodycote had completed 27 of 31 planned closures or disposals of weaker sites by the half-year. It had also begun an £80 million share buyback, repurchasing 1.9 million shares at an average of about 680p, well below the eventual offer price. Management left its full-year outlook unchanged, expecting core organic revenue growth and improved operating margins in 2026.

Conditions and Timetable

The Veritas offer is being implemented by a scheme of arrangement and needs the approval of 75 per cent of votes cast by shareholders, as well as court sanction and a range of competition and regulatory clearances listed in the offer document. Completion is expected in the first quarter of 2027. Veritas is funding the deal with a combination of capital from its funds and committed Debt facilities.

Separately, on the board, non-executive director Cynthia Gordon stepped down on 23 September 2026, with Emmanuelle Dubu taking over as chair of the remuneration committee.

Risks and Open Questions

Several uncertainties remain. The first is whether CVC, or another party, returns with a higher offer. Shares trading above the agreed price suggest the market sees some chance of that, but a counterbid is not guaranteed, and if one does not materialise the premium built into the share price could unwind.

The second is regulatory timing. With facilities across many jurisdictions and a growing aerospace and defence business, clearances could take time, and the deal could Fail if conditions are not met.

Third, for shareholders who would prefer to stay invested, a takeover would mean losing exposure to a recovery that management argues is still at an early stage, with margin gains from Optimise and a growing share of higher-value work. Automotive weakness in Western Europe and broader industrial cycles remain headwinds for the underlying business in the meantime.

Milestones to Watch

  • Any statement from CVC on whether it will make a competing offer
  • Publication of the scheme document and the dates of the court and Shareholder meetings
  • Progress on the regulatory approvals listed in the offer conditions
  • Any further trading update from Bodycote while the offer is pending

The Takeaway

Bodycote is in the spotlight because two well-funded private capital buyers have competed for it. Veritas's 940p offer carries the board's backing and a substantial premium to where the shares traded in early July, supported by improving results. Whether that price holds, or whether CVC returns, is the key question for the weeks ahead, alongside the regulatory path to completion.